Lapatinib shows promise as therapy for inflammatory breast cancer

Armen Hareyan's picture
Advertisement

Inflammatory breast cancer treatment

In the first multi-center and international clinical trial conducted to better understand the complexities of a rare, aggressive and often lethal form of breast cancer, researchers have discovered that the experimental biological agent, lapatinib, successfully and specifically treats inflammatory breast cancer (IBC).

Advertisement

Massimo Cristofanilli, M.D., associate professor in the Department of Breast Medical Oncology at The University of Texas M. D. Anderson Cancer Center, reported the findings of the international Phase II trial today at the San Antonio Breast Cancer Symposium.

IBC is rare, representing just 1- 2 percent of all breast cancers diagnosed. Unlike other breast cancers that present as a lump,

Advertisement